Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MorphoSys Strengthens Patent Position on anti-CD38 Cancer Program MOR202

Published: Thursday, December 06, 2012
Last Updated: Thursday, December 06, 2012
Bookmark and Share
New patent covers functional properties of anti-CD38 antibodies.

MorphoSys AG has announced that the US Patent and Trademark Office (USPTO) has granted a patent covering the Company's cancer compound MOR202.

The new patent (US 8,263,746) covers functional properties of anti-CD38 antibodies and provides additional patent protection for MorphoSys's HuCAL antibody MOR202.

The newly issued patent adds to the US patent granted earlier this year covering the antibody's protein sequence as well as pharmaceutical compositions comprising the same.

Together, the two patent families provide strong intellectual property protection for the MOR202 program.

The new patent has a scheduled expiry date in 2025, not including any potential patent office or regulatory extensions.

Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG, commented: "Antibodies targeting CD38 are gathering increased interest from the pharmaceutical industry as a new potential treatment option in multiple myeloma and other forms of leukemia. As with our other proprietary programs, our goal is to build a rich scientific, medical and commercial package around MOR202 in order to lay the groundwork for future partnering. This new patent widens the scope of our patent position around the MOR202 program by covering the functional aspects of anti-CD38 antibodies in addition to protecting the individual antibody sequence."

MOR202 is a fully human HuCAL antibody directed against CD38, a therapeutic target for the treatment of multiple myeloma and certain forms of leukemia.

The fully human HuCAL-antibody is currently being tested in a phase 1/2a trial in patients with relapsed/refractory multiple myeloma.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MorphoSys, MD Anderson Partner
MorphoSys AG and The University of Texas MD Anderson Cancer Center have announced a long-term strategic alliance for the discovery and development of novel therapeutic antibodies against cancer.
Wednesday, May 25, 2016
MorphoSys Announces Clinical Milestone for Start of Bayer's Phase 2 Trial
Phase 2 trial designed to support registration of anetumab ravtansine.
Wednesday, January 27, 2016
MorphoSys Presents Safety and Efficacy Data for MOR202 at ASH Meeting
MOR202 exhibits encouraging clinical activity and good safety profile with best-in-class infusion tolerability.
Tuesday, December 08, 2015
MorphoSys Publishes Update on MOR202 in Multiple Myeloma
First data from final 16 mg/kg dose escalation cohort and combination with immunomodulatory drugs show encouraging activity.
Thursday, September 24, 2015
MorphoSys Provides an Update on its Proprietary Development Portfolio
Lead cancer program MOR208 to be examined in numerous combination studies in hematological cancers.
Thursday, September 10, 2015
MorphoSys and Immatics Enter Strategic Alliance in Immuno-oncology
Collaboration aims to develop novel antibody-based therapies targeting tumor-associated peptides derived from intracellular proteins.
Tuesday, August 25, 2015
MorphoSys AG Reports Results for the First Six Months of 2015
Therapeutic pipeline exceeds 100 drug candidates in research & development.
Saturday, August 08, 2015
MorphoSys's Partner Heptares Initiates Proprietary Therapeutic Antibody Program
Successful discovery alliance combines two leading technologies.
Thursday, August 06, 2015
MorphoSys and G7 Therapeutics Sign Alliance
Collaboration broadens MorphoSys' capabilities to target novel antigen classes.
Thursday, August 06, 2015
MorphoSys Announces Clinical Milestone in Blood Disorders Program
Company has received milestone payment from Novartis.
Saturday, July 25, 2015
MorphoSys Presents Updated Phase 2 Clinical Results for MOR208
Matured data set shows six complete remissions with durable responses in diffuse large B-cell lymphoma and follicular lymphoma.
Thursday, June 04, 2015
MorphoSys Presents First Safety, Pharmacokinetic and Efficacy Data for MOR202
Clinical activity and long-lasting tumor control already observed at low doses.
Wednesday, June 03, 2015
MorphoSys to Present Data on Proprietary Programs at 20th Congress of EHA
Substantial data packages on lead compounds MOR202 and MOR208.
Tuesday, May 26, 2015
MorphoSys to Present Data on Proprietary Programs at ASCO Annual Meeting
Abstracts include first clinical data for MOR202.
Tuesday, May 26, 2015
MorphoSys AG Reports Results for the First Three Months of 2015
First quarter positively impacted by one-off effects relating to MOR202.
Tuesday, May 12, 2015
Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Manufactured Stem Cells to Advance Clinical Research
Clinical-grade cell line will enable development of new therapies and accelerate early-stage clinical research.
Dengue Virus Exposure May Amplify Zika Infection
Researchers at Imperial College London have found that the previous exposure to the dengue virus may increase the potency of Zika infection.
Gender Determination in Forensic Investigations
This study investigated the effectiveness of lip print analysis as a tool in gender determination.
Identifying Novel Types of Forensic Markers in Degraded DNA
Scientists have tried to verify the nucleosome protection hypothesis by discovering STRs within nucleosome core regions, using whole genome sequencing.
Proteins in Blood of Heart Disease Patients May Predict Adverse Events
Nine-protein test shown superior to conventional assessments of risk.
Higher Frequency of Huntington's Disease Mutations Discovered
University of Aberdeen study shows that the gene change that causes Huntington's disease is much more common than previously thought.
Starving Stem Cells May Enable Scientists To Build Better Blood Vessels
Researchers from the University of Illinois at Chicago College of Medicine have uncovered how changes in metabolism of human embryonic stem cells help coax them to mature into specific cell types — and may improve their function in engineered organs or tissues.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!